OTOP3 inhibitors are a class of chemical compounds designed to specifically block the function of the OTOP3 protein, which is a member of the otopetrin family of proton channels. These inhibitors act by binding to OTOP3 at key sites, which either directly obstruct the channel or induce conformational changes that prevent the normal passage of protons. The OTOP3 protein is embedded in the cell membrane, and its activity is crucial for modulating ion flux across the membrane, affecting cellular processes such as pH regulation and ionic balance. OTOP3 inhibitors are typically designed with high specificity in mind, allowing them to selectively bind to OTOP3 without affecting other members of the otopetrin family or similar ion channels. This specificity is achieved through the careful consideration of the molecular structure, targeting features like unique residues in the binding pocket of OTOP3 that are absent in related proteins.
The development of OTOP3 inhibitors relies heavily on structural biology and computational modeling to accurately determine the binding sites and identify critical interaction points. Techniques like cryo-electron microscopy (cryo-EM) and homology modeling help elucidate the structure of OTOP3, enabling researchers to pinpoint potential inhibitory sites that could be exploited for selective binding. Molecular dynamics simulations and docking studies are used to screen potential inhibitors and optimize their interactions with the protein. Chemical modifications such as the addition of hydrophobic groups, aromatic rings for π-π interactions, or ionizable groups for electrostatic interactions are often performed to enhance binding affinity and inhibitor potency. These inhibitors can vary widely in size and complexity, from small organic molecules to more elaborate structures, depending on the intended mechanism of action. Additionally, the physicochemical properties of OTOP3 inhibitors, including solubility, stability, and membrane permeability, are key factors that need to be optimized to ensure effective inhibition of OTOP3 function. The intricate design of these inhibitors highlights the importance of a detailed understanding of protein structure and function, as well as the application of synthetic chemistry and structure-activity relationships (SAR) to achieve precise and potent modulation of target activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $56.00 | 6 | |
Inhibits sodium channels and may interfere with ion balance, possibly affecting the ionic environment essential for OTOP3 function. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $107.00 $224.00 | 9 | |
Inhibits Na-K-Cl cotransporter and could disturb ion gradients, potentially altering OTOP3 activity if it is sensitive to these ions. | ||||||
Ouabain-d3 (Major) | sc-478417 | 1 mg | $506.00 | |||
Inhibits Na+/K+-ATPase and can disrupt ion homeostasis, which may indirectly affect the function of OTOP3 if it relies on ion flux. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Antagonizes dopamine receptors and may alter intracellular signaling, leading to changes in OTOP3 activity if it is regulated by dopaminergic pathways. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylate cyclase and increases cAMP, which could modulate OTOP3 activity if it is cAMP-responsive. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
Modulates IP3 receptors and could affect calcium signaling, altering OTOP3 activity if it is regulated by calcium levels. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
A tyrosine kinase inhibitor that may alter phosphorylation states of proteins, including OTOP3 if it undergoes tyrosine phosphorylation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK and could affect the MAPK/ERK pathway, potentially altering OTOP3 activity if it is downstream of this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K and could affect the PI3K/Akt pathway, potentially altering OTOP3 activity if it is regulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK and could alter stress response pathways, possibly affecting OTOP3 activity if it is stress-responsive. |